How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals reported mixed Q2 results, with revenue declining to $7.67 million and net losses narrowing to $131.01 million. Significant milestones include FDA clearance for a new trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results